Document is current
Any future updates will be listed below
-
Authors
Sanchez, Katherine
Kim, Isaac
Chun, Brie
Pucilowska, Joanna
Redmond, William L.
Urba, Walter J.
Martel, Maritza
Wu, Yaping
Campbell, Mary
Sun, Zhaoyu
Grunkemeier, Gary
Chang, Shu Ching
Bernard, Brady
Page, David B. http://orcid.org/0000-0001-9264-4628
-
Funding
Funding for this research was provided by:
Brooklyn Immunotherapeutics
Providence Portland Medical Foundation
- License Information
-
More Information
Article History
Received: 27 April 2020
Accepted: 3 December 2020
First Online: 7 January 2021
Ethics approval and consent to participate
: The clinical trial was approved and overseen by the Providence Health & Services Institutional Review Board. Informed consent was obtained per institutional guidelines for each subject.
: Not applicable.
: KS has no competing interests to declare.IK has no competing interests to declare.BC has no competing interests to declare.JP has no competing interests to declare.WR has received research funding from Bristol-Myers Squibb, Merck, Nektar Therapeutics, GSK, Galectin Therapeutics, Inhibrx, Oncosec, Aeglea Biotherapeutics, Veana Therapeutics, and MiNA Therapeutics. WR has also received advisory board honoraria from Nektar Therapeutics and serves on the advisory board of Vesselon, Inc.WU has no competing interests to declare.MM has no competing interests to declare.YW has no competing interests to declare.MC has no competing interests to declare.ZS has no competing interests to declare.GG has no competing interests to declare.SC has no competing interests to declare.BB has no competing interests to declare.DP has received advisory board honoraria and institutional research funding support from Brooklyn ImmunoTherapeutics, Bristol-Myers Squibb, and Merck Laboratories. DP receives speaker bureau honoraria from Genentech and Novartis. Unrelated to this work, DP has received additional advisory board honoraria from other entities.
